10-Q: XOMA Royalty Corporation Reports Net Income of $2.4 Million for Q1 2025
Quarterly Report
XOMA Royalty Corporation announces a net income of $2.4 million for the first quarter of 2025, driven by increased revenue from purchased receivables and strategic acquisitions.
Summary
- XOMA Royalty Corporation reported a net income of $2.4 million for the three months ended March 31, 2025.
- This is a significant improvement compared to the net loss of $8.6 million for the same period in 2024.
- The company's cash and cash equivalents totaled $90.3 million as of March 31, 2025.
- Total income and revenues increased to $15.9 million, up from $1.5 million in Q1 2024.
- The increase in revenue was primarily driven by income from purchased receivables under the EIR method and revenue from contracts with customers.
- Research and development expenses increased to $1.3 million, mainly due to pass-through licensing fees and clinical trial costs.
- General and administrative expenses decreased slightly to $8.1 million.
- The company's stock repurchase program continued, with 25,828 shares repurchased during the quarter for $0.5 million.
- XOMA believes its current financial resources are sufficient to fund planned operations for at least one year.
Sentiment
Score: 7
Explanation: The document presents a positive outlook with improved financial performance and strategic acquisitions. However, risks related to the industry and dependence on partners' success temper the overall sentiment.
Positives
- The company achieved net income of $2.4 million, a significant improvement from the previous year.
- Total income and revenues increased substantially, driven by key revenue streams.
- Strategic acquisitions and collaborations are contributing to revenue growth.
- The company believes its current financial resources are sufficient to fund planned operations for at least one year.
- The company is receiving commercial payments pursuant to the Affitech CPPA of $11.1 million.
Negatives
- Research and development expenses increased, primarily due to pass-through licensing fees and clinical trial costs.
- The company has an accumulated deficit of $1.2 billion as of March 31, 2025.
Risks
- The generation of future revenues and income is dependent on the achievement of milestones or product sales by existing partners.
- The company's ability to raise additional capital is dependent on market conditions and other factors.
- Disruptions at the FDA and other government agencies could negatively affect the review of regulatory submissions.
- Macroeconomic conditions, including inflation and geopolitical conflicts, could adversely affect the company's results of operations.
Future Outlook
XOMA expects income related to VABYSMO and royalties on OJEMDA to increase in future periods as sales increase. The company believes its current financial resources are sufficient to fund planned operations for at least one year.
Industry Context
XOMA operates in the biotech royalty aggregator space, acquiring rights to future milestone and royalty payments. The company's performance is tied to the success of its partners' drug development and commercialization efforts. The industry is subject to regulatory risks, market volatility, and competition from other royalty aggregators.
Comparison to Industry Standards
- It is difficult to compare XOMA's results directly to industry standards due to the unique nature of its royalty aggregator business model.
- However, comparable companies in the royalty space include DRI Healthcare Trust and Ligand Pharmaceuticals.
- DRI Healthcare Trust focuses on acquiring royalties on approved pharmaceutical products, while Ligand Pharmaceuticals uses a platform technology approach to generate royalties.
- XOMA's focus on early to mid-stage clinical assets differentiates it from some of its peers.
- The company's Q1 2025 net income of $2.4 million represents a significant improvement compared to its performance in Q1 2024, indicating a positive trend in its financial performance.
Stakeholder Impact
- Shareholders will benefit from the improved financial performance and potential for future growth.
- Employees will benefit from the company's continued operations and strategic initiatives.
- Customers (licensees and partners) will benefit from the company's continued investment in its portfolio.
- Suppliers and creditors will benefit from the company's financial stability and ability to meet its obligations.
Next Steps
- Continue to monitor the performance of VABYSMO and OJEMDA.
- Evaluate potential acquisitions of milestone payments and royalty streams.
- Manage operating expenses and maintain sufficient capital resources.
Key Dates
| Date | Description |
|---|---|
| 2006-11-01 | XOMA entered into a Collaboration Agreement with Takeda. |
| 2016-12-01 | XOMA entered into two royalty interest sale agreements with HCRP. |
| 2017-12-06 | XOMA entered into a license agreement with Rezolute. |
| 2019-08-01 | XOMA entered into an agreement with Janssen. |
| 2019-09-26 | XOMA entered into the Palo RPA. |
| 2021-03-22 | XOMA entered into the Viracta RPA. |
| 2021-07-14 | XOMA entered into the Kuros RPA. |
| 2021-08-05 | XOMA entered into the 2021 Series B Preferred Stock ATM Agreement with B. Riley. |
| 2021-10-06 | XOMA entered into the Affitech CPPA. |
| 2023-03-29 | XOMA entered into the Aptevo CPPA. |
| 2023-06-21 | XOMA entered into the LadRx AAA. |
| 2023-12-15 | XRL entered into the Blue Owl Loan Agreement with Blue Owl and lenders. |
| 2024-01-02 | The Board authorized XOMA's stock repurchase program. |
| 2024-02-16 | XOMA entered into the Agreement and Plan of Merger with Kinnate. |
| 2024-04-03 | XOMA completed the acquisition of Kinnate. |
| 2024-10-01 | XOMA reclassified $7.2 million of royalty and commercial payment receivables under the cost recovery method to royalty and commercial payment receivables under the EIR method related to Aptevo. |
| 2024-10-31 | XOMA entered into the Twist RPA. |
| 2024-11-26 | The Company acquired Pulmokine for $20.5 million. |
| 2024-12-19 | Alexion exercised an option to continue developing anti-PTH1R monoclonal antibodies. |
| 2025-02-24 | XOMA entered into a royalty financing transaction with Castle Creek Biosciences, Inc. and Castle Creek Biosciences, LLC. |
| 2025-03-31 | End of the quarterly period. |
| 2025-04-02 | XOMA completed the sale of all five pipeline assets that were acquired in the acquisition of Kinnate Biopharma Inc. |
| 2027-01-02 | End date of the stock repurchase program. |
Keywords
royalty, milestone, revenue, acquisition, pharmaceutical, biotech, XOMA, VABYSMO, IXINITY, OJEMDA, D-Fi, seralutinib
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.